Table 2 Adverse events reported by ≥5.0% of subjects in any treatment arm in the STAR study [27]

From: Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA®) for Pseudobulbar Affect

Adverse event Incidence, N (% of group)
DM/Q 30/10 mg (N = 110) DM/Q 20/10 mg (N = 107) Placebo (N = 109)
Fall 22 (20.0) 14 (13.1) 22 (20.2)
Dizziness 20 (18.2) 11 (10.3) 6 (5.5)
Headache 15 (13.6) 15 (14.0) 17 (15.6)
Nausea 14 (12.7) 8 (7.5) 10 (9.2)
Diarrhea 11 (10.0) 14 (13.1) 7 (6.4)
Somnolence 11 (10.0) 9 (8.4) 10 (9.2)
Fatigue 9 (8.2) 11 (10.3) 10 (9.2)
Nasopharyngitis 9 (8.2) 6 (5.6) 8 (7.3)
Urinary tract infection 8 (7.3) 4 (3.7) 3 (2.8)
Constipation 7 (6.4) 7 (6.5) 9 (8.3)
Muscle spasms 7 (6.4) 4 (3.7) 10 (9.2)
Muscle weakness 6 (5.5) 5 (4.7) 4 (3.7)
Dysphagia 5 (4.5) 6 (5.6) 4 (3.7)
Pain in extremity 5 (4.5) 2 (1.9) 8 (7.3)
Depression 0 (0.0) 1 (0.9) 6 (5.5)
  1. Adapted from Pioro et al. [27] with permission from John Wiley & Sons, Inc. © 2010 American Neurological Association
  2. DM/Q, dextromethorphan/quinidine, STAR Safety, Tolerability, and Efficacy Results